Cite
HARVARD Citation
Menter, A. et al. (2021). Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert opinion on biological therapy. pp. 87-96. [Online].